NCT04706598进行中（未招募）1 期
A Phase I/II Single Arm Study of Intravesical Administration With Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer(NMIBC) Failing in BCG Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
- 试验地点
- 4
- 主要终点
- The maximum dose of Camrelizumab for intravesical treatment
研究概览
简要总结
This study will evaluate the safety and efficacy of bladder intravesical Camrelizumab in patients with high-risk non-muscle-invasive bladder cancer who failed BCG therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Histologically-confirmed diagnosis of high risk non-muscle-invasive urothelial cell carcinoma of the bladder (mixed histology tumors allowed if urothelial carcinoma histology is >50%).
- •Fully resected disease at study entry (residual CIS acceptable).
- •BCG-unresponsive high risk non-muscle-invasive bladder cancer after treatment with adequate BCG therapy(at least five times a week during the induction phase and at least two times a week during the maintenance phase).
- •Ineligible for radical cystectomy or refusal of radical cystectomy.
- •Consent to tissue specimen retrieval and testing.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate normal organ and marrow function as defined below:
- •Haemoglobin (HB) ≥ 90 g/L
- •Absolute neutrophil count (ANC) ≥1.5×10^9/L(no granulocyte colony-stimulating factor support for 2 weeks before day 1 of cycle 1)
- •Lymphocyte count≥0.500×10^9/L
- •Platelet count ≥100×10^9/L(No blood transfusions within 2 weeks before day 1 of cycle 1)
- •4.0×10^9/L≤White Blood Cell Count (WBC)≤15×10^9/L
- •AST (SGOT)/ALT (SGPT)/Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal(ULN) (excluded Gilbert's disease patients, whose serum bilirubin level ≤ 3x ULN)
- •INR/aPTT≤1.5×ULN(Which only applies to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be given a stable dose)
- •Serum creatinine (Cr) ≤ 1.5 times the upper institutional limit of normal (ULN) or Serum creatinine Cl>60 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976)
- •Women of childbearing potential who have a negative serum pregnancy test within 72 hours prior to the first dose should consent to and must use effective contraception during and for 6 months after the end of the study.
- •Men should consent to patients who must use contraception during the study and for 6 months after the end of the study period.
- •The subject is personally willing and able to provide written informed consent to be able to comply with the protocol.
排除标准
- •Muscle-invasive, locally advanced nonresectable, or metastatic urothelial carcinoma.
- •Concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis)urothelial cell carcinoma.
- •Have participated in a clinical trial of an investigational drug or device within 4 weeks prior to receiving the first treatment in this project.
- •Received chemotherapy, targeted small molecule therapy, immunotherapy or radiation therapy following a recent cystoscopy or transurethral resection of a bladder tumour.
- •History of other malignancies within the last 5 years.
- •Active autoimmune disease that has required systemic treatment in the past 2 years.
- •History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonia, histoplasmosis (i.e. occlusive bronchiolitis, cryptogenic histoplasmosis), or evidence of active pneumonia on chest CT scan (history of fibrosis in radiation pneumonia), patients with active tuberculosis.
- •Active infection requiring systemic therapy,therapeutic oral or intravenous (IV) antibiotics within 14 days prior to enrolment (patients receiving prophylactic antibiotics (e.g. for the prevention of urinary tract infections or chronic obstructive pulmonary disease) can be enrolled).
- •Patients who are pregnant or breastfeeding, or expecting to conceive .
- •Previous treatment with anti-PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA-4 monoclonal antibody, or other drugs that act on T-cell co-stimulation or any other antibody of the checkpoint pathway.
- •Patients with known positive test for human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
- •Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (Hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU/ml; Hepatitis C reference: HCV antibody positive and HCV viral copy number > upper limit of normal value).
- •Received a live virus vaccine within 30 days of planned start of study treatment.
- •Has had an allogeneic tissue/solid organ transplant.
- •Long-term oral steroids, more than 10 mg/day of methandrostenolone or similar, must be stopped for 28 days before entry into the group.
- •Evidence of apparently uncontrolled concomitant disease that may affect compliance with the protocol or interpretation of the results, including significant liver disease (e.g. cirrhosis, uncontrolled major seizures or superior vena cava syndrome).
- •Significant cardiovascular disease, such as New York Heart Association heart attack (class II or higher), myocardial infarction, unstable arrhythmia or unstable angina within 3 months prior to study entry.
- •Patients who have had major surgery within 4 weeks prior to study entry, or who are expected to require major surgery during the course of the study, except diagnostic procedures such as TURBT or biopsy.
- •History of autoimmune diseases, including but not limited to severe muscle weakness, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, angio-thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, dry syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
- •History of severe allergy, sensitisation or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins.
- •Patients who, in the opinion of the investigator, are otherwise unable to participate in this trial.
研究组 & 干预措施
Intravesical therapy group
Experimental
Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.
The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years.
干预措施: Camrelizumab (Drug)
结局指标
主要结局
The maximum dose of Camrelizumab for intravesical treatment
时间窗: 3 months after trial initiation(Phase I)
The maximum tolerated dose (MTD) of Camrelizumab that will be given intravesically to patients with BCG-refractory NMIBC(de-escalated doses of 200/150/100mg) and recommended for phase II studies (RP2D).
Event-Free Survival (EFS)
时间窗: 3 months after patient treatment (Phase II)
Recurrence of high-grade cancer (TaHG, T1HG, CIS), or disease progression to stage T2 or beyond or lymph node metastasis or distant metastasis, or the need for other treatment (including systemic chemotherapy, radical cystectomy, radiation therapy), and death from any cause.
次要结局
- Assessment of RFS(6 months and 1 year after patient enrollment)
- Incidence of adverse events(Until progressive disease or death)
- Assessment of HGRF(6 months and 1 year after patient enrollment)
- Assessment of PFS(6 months and 1 year after patient enrollment)
- the predictive value of PD-1 expresssion(1 year after patient enrollment)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2High-risk Non-muscle Invasive Bladder CancerNCT06378242RemeGen Co., Ltd.24
已完成
1 期
VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerBladder CancerNCT02371447Swiss Group for Clinical Cancer Research39
进行中（未招募）
1 期
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderUrothelial Carcinoma of the Urinary BladderNCT02202772Guarionex J. Decastro51
已完成
1 期
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the BladderBladder CancerNCT01259063Memorial Sloan Kettering Cancer Center33
已完成
1 期
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerNon-muscle Invasive Bladder CancerNCT01458847BioCis Pharma Ltd12